Content Type: Article

  • 7 Tips to Avoid Compliance Missteps During Open Enrollment

    ARTICLE

    7 Tips to Avoid Compliance Missteps During Open Enrollment

    October 30, 2018

    Read time: 2 min

    Key takeaways
    Overview

    Megan Mardy, Jacob Mattinson, and Emily Rickard authored this bylined article on key employee benefits issues to consider to help avoid compliance mistakes during the annual open enrollment period.

    In depth
    Authors

    Jacob M. Mattinson

    Partner

    Chicago

    More insights

  • International Legal Highlights – October 2018

    ARTICLE

    International Legal Highlights – October 2018

    October 2018

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Much Needed Updates to Employee Benefit Plan Disclosure Rules

    ARTICLE

    Much Needed Updates to Employee Benefit Plan Disclosure Rules

    October 2018

    Read time: 2 min

    Key takeaways
    Overview

    Jacob Mattinson and Erin Turley authored this book chapter exploring the regulatory environment governing the distribution of legally required employee benefit plan communications and offering recommendations to update these rules.

    In depth
    Authors
    More insights

  • CMS Requests Comment on Potential International Pricing Index Model for Part B Drugs

    CMS Requests Comment on Potential International Pricing Index Model for Part B Drugs

    ARTICLE / CLIENT ALERT

    CMS Requests Comment on Potential International Pricing Index Model for Part B Drugs

    October 29, 2018

    Read time: 23 min

    Key takeaways
    Overview

    On October 25, 2018, the Centers for Medicare and Medicaid Services (CMS) announced an Advance Notice of Proposed Rulemaking with Comment (ANPRM) proposing to implement an international pricing index (IPI) model for Medicare Part B drugs and biologicals (IPI Model). Part B drugs and biologicals include many drugs and biologicals administered by physicians in physician offices and hospital outpatient departments. If implemented, the proposed model would make sweeping changes to the drug and biological supply chain for participants, and would pose a variety of expected and unknown implications for drug and biological manufacturers, distributors, group purchasing organizations (GPOs), hospitals and physician clinics, among other industry stakeholders.

    CMS is accepting public comments on the ANPRM until December 31, 2018, and is considering issuing a proposed rule in spring 2019. The model would be implemented in spring 2020 and operate for five years. This On the Subject provides a comprehensive list of CMS’s requests for comment at Appendix A.

    This On The Subject was co-authored by John Warren, Senior Director, McDermott+Consulting.

    In depth

    The backdrop for this ANPRM is the American Patients First Blueprint, a plan to lower drug prices and reduce beneficiary out-of-pocket spending on drugs in the Medicare program, released by President Trump on May 11, 2018. The Blueprint builds upon a trio of documents released earlier in 2018 that together provide the framework for a multi-faceted approach that the administration believes can reduce spending on prescription drugs in the United States while continuing to encourage growth and innovation. In the Blueprint, President Trump attempts to determine why prescription drug pricing continues to rise, and questions why the United States pays more for prescription drugs than its international allies. The Blueprint directs the US Department of Health and Human Services (HHS) to develop demonstration projects to test innovative ways to encourage value-based care and lower drug prices.

    The ANPRM’s proposals are preliminary, and it remains uncertain whether any will ultimately become implemented. If CMS determines to move forward with the IPI Model after reviewing public comments to the ANPRM, CMS would presumably publish a proposed rule that could modify the initially proposed IPI Model (discussed in-depth below). The proposed rule would offer the public another opportunity for comment, and CMS may ultimately determine not to finalize the proposals even after publishing a proposed rule. Alternatively, CMS could modify the proposals set forth in the proposed rule before it becomes finalized. In sum, public responses to the ANPRM and any subsequent proposed rule, as well as various political and regulatory considerations, have the potential to impact whether or how its proposals become implemented.

    If the IPI Model were finalized as initially proposed, participating physicians, hospital outpatient departments and entities that CMS may decide to include following review of public comments (collectively, Participants) would no longer purchase and bill Medicare for Part B drugs and biologicals. Instead, they would enroll with “model vendors” to obtain Part B drugs and biologicals that they administer to patients. Medicare would continue to pay Participants for the administration of the drug and would pay an additional “add-on” payment for drugs and biologicals furnished to beneficiaries, but the add-on payment amount would be intended only to cover lost revenue and limited administrative costs. Model vendors would enroll with Medicare as suppliers and negotiate contracts with manufacturers to purchase drugs and biologicals to distribute to Participants, and Participants would hold distribution contracts with model vendors. Under the IPI Model, Medicare payment rates for included Part B drugs and biologicals would be adjusted using an indexing formula, such that domestic Medicare payment rates would more closely match international prices for each Part B drug or biological covered by the model.

    Model Vendors

    The model contemplates that commercial entities such as GPOs, wholesalers, distributors, specialty pharmacies, individual or groups of physicians and hospitals, manufacturers, Part D sponsors and/or other entities would be eligible to enroll as model vendors. These model vendors would negotiate the acquisition prices for drugs and biologicals and take title of the drugs and biologicals, but they would not be required to take physical possession of the products. Model vendors would enroll Participants and establish mechanisms to receive compensation from Participants for their services. Model vendors would enroll in Medicare in a manner similar to other Medicare suppliers. The model vendors would submit claims to Medicare for included drugs distributed to Participants and furnished to Medicare beneficiaries. Periodically, CMS would ensure that payment to model vendors for administered drugs was substantiated by the Participant-submitted claims. CMS intends to select three or more model vendors, each of which would be required to be able to work with all Participants regardless of geographic location, so that Participants have several options and model vendors compete on the basis of customer service and cost.

    Model Participants, Selected Geographies and Compensation

    Model participants would include all physician practices and hospital outpatient departments that furnished the model’s included drugs in the selected model geographic locations. CMS is seeking comments on whether to include in the model durable medical equipment (DME) suppliers, Ambulatory Surgical Centers (ASCs), or other Part B providers and suppliers that furnish the included drugs. Medicare anticipates that the spending on Part B drugs and biologicals in selected geographic areas would reflect 50 percent of Medicare Part B spending on separately payable Part B drugs. CMS is considering a randomized design with randomization of geographic areas to intervention and comparison groups. CMS is considering Core Based Statistical Areas (CBSAs) as the primary geographic unit of analysis in the model; however, CMS is also considering aggregations of CBSAs, such as metropolitan statistical areas or combined statistical areas, as alternative approaches.

    Under the model, Participants would continue to be paid for drug administration services and receive an additional “add-on” payment to help cover the costs of drug ordering, storage and handling, and other costs associated with furnishing these drugs to Medicare beneficiaries. The add-on payment is proposed as a set amount, paid either per encounter or per month for an administered drug; the payment amount would not vary based on the payment amount for the drug itself. CMS contemplates calculating the add-on payment amount by each class of drug, physician specialty or physician practice (or hospital). The final payment amount would be calculated annually based on 6 percent of ASP revenue that model participants would have garnered without sequestration in the most recent year of claims data.

    In other words, it appears that CMS is proposing to use the most recent year of available claims data to calculate the total amount of add-on payments a Participant would have received over the course of a year under the standard payment model absent sequestration (ASP plus 6 percent), and to divide that amount by 12 (if CMS moves forward with a per-month payment structure) or the anticipated number of patient encounters (if CMS moves forward with an per-encounter payment structure), to calculate a per-month or per-encounter add-on payment rate for Participants. CMS acknowledged in the ANPRM that total model payments to Participants would vary based on utilization under an encounter-based model, and CMS intends to monitor drug utilization carefully throughout the model “to ensure beneficiary access to drugs is not compromised.”

    Included Drugs and Biologicals

    As proposed, the model would initially cover single source drugs and biologicals (including biosimilars) administered incident to a physician’s services. CMS explained that it selected these categories of drugs because they encompass most of Medicare’s Part B drug spending (approximately 84 percent, or $23.6 billion, based on 2016 data). CMS provided a few examples of included drugs, such as cancer drugs and adjunct therapy for cancer and related conditions, biologicals used for the treatment of rheumatoid arthritis and other immune mediated conditions, and drugs used to treat macular degeneration. For purposes of the model, CMS stated that it would also include HCPCS codes that contain only products with a single manufacturer, even if they are multiple source drugs. Notably, CMS intends to broaden the scope of included drugs beginning in year three of the model.

    CMS also stated that it is considering excluding (1) drugs that are identified by the US Food and Drug Administration (FDA) to be in short supply, and (2) drugs paid under miscellaneous or “not otherwise classified” (NOC) codes, such as J3490, because of the operational complexity of identifying whether drugs paid under the NOC codes are included model drugs.

    Payment Methodology

    CMS is considering testing an alternative payment rate for included drugs based on international prices, except where the ASP is lower. Medicare payment for separately payable Part B drugs is typically based on ASP of a given drug, plus 6 percent of the ASP as an add-on payment. For the IPI Model, CMS proposes to calculate the model payment to model vendors for included drugs through a multi-step process that considers the “average international price” in certain countries for each Part B drug included in the model, the volume of included drugs reimbursed by Medicare, and an unspecified “factor” that would “more closely align Medicare payment with international prices.” More specifically:

    • CMS would calculate an average international price for each Part B drug included in the model based on a standard unit that is comparable to that in the drug HCPCS code.
    • CMS would then calculate the ratio of Medicare spending using ASP prices for all Part B drugs included in the model to estimated spending using international prices for the same number and set of drugs by multiplying Part B volumes by the ASP prices and then by the international prices. The resulting ratio of Medicare spending under ASP versus Medicare spending under the international prices holding volume and mix of drugs constant would represent the IPI.
    • CMS would also establish the model target price for each drug by multiplying the IPI by a factor that would more closely align Medicare payment with international prices, and then multiplying that revised index (IPI adjusted for spending reduction) by the international price for each included drug. CMS would calibrate the revised index to account for any drugs with ASP below the target price.

    CMS proposes to phase-in the target price over the five years of the model, as a blend of ASP and the target price. For each calculation, if ASP is lower than the target price for an included drug, CMS proposes that the model would set the payment amount to the ASP for that drug. As with current Part B drug payments, CMS stated that it would plan to update the model payment amount for each drug periodically based on new ASP and international pricing data.

    Interaction with Other Federal Programs

    CMS described several potential interactions with other federal programs in the ANPRM and seeks comment on how to avoid unintended consequences arising from such interactions, listing potential impacts on (1) manufacturer’s best price and resulting increase Medicaid rebates, (2) the average manufacturer price, and (3) the 340B program. Interestingly, CMS only acknowledges the potential for an impact on 340B ceiling price calculations and does not address the lost opportunity for 340B purchasing or the potential conflict with the group purchasing arrangement prohibition.

    Analysis

    Recent experience suggests that sweeping administrative changes to Part B drug reimbursement will be met with fierce public opposition that may ultimately defeat implementation. As recently as March 2016, CMS proposed a demonstration model that would have effected significant changes to Medicare reimbursement for Part B drugs. The model was withdrawn prior to finalization in response to widespread concerns relating to the model’s impact on Part B drug accessibility and adverse implications for industry stakeholders, among other concerns. At this time, it is unclear whether any of the ANPRM’s proposals will ultimately be implemented, considering their potential sweeping implications. However, the ANPRM and statements from President Trump and Secretary Alex Azar on October 25, 2018, suggest robust political interest in the implementation of the ANPRM’s proposals.

    Although the ANPRM proposes only general frameworks and solicits comments that indicate that even these basic frameworks may shift, the ANPRM raises a variety of potential implications, unintended consequences and concerns for industry stakeholders and policy makers to consider. From a general financial standpoint, a reduction in Medicare reimbursement for Part B drugs and biologicals furnished by model participants could unintentionally require a counterbalancing of prices for drugs and biologicals not purchased and furnished as part of the model. The ANPRM provides an opportunity for manufacturers, providers, GPOs and other interested parties to explain to policy makers the variety of adverse unintended consequences that could flow from the model’s implementation, while at the same time signaling that industry stakeholders may need to engage in robust strategic planning to successfully navigate implementation of the IPI Model.

    The model makes a number of presumptions about pricing behaviors in both domestic and international markets that are untested. While many have studied prices in the international drug market, information about those international markets is still incomplete. For instance, it is unclear if the prices set under a single-payer system can or should be compared to prices set under a multi-payer system.

    Beyond pricing implications outside of the model, the model would generate a variety of compliance considerations for manufacturers and model vendors. The ANPRM suggests drug and biological manufacturers may be required to report international drug sale information on a quarterly basis, although the specific requirements for these reports are yet to be determined. Model vendors would be required to enroll in Medicare as suppliers and presumably meet the myriad compliance requirements and risks associated with Medicare enrollment and billing Federal Health Care Programs for Designated Health Services (e.g., direct liability under the federal Anti-Kickback Statute, Stark Law, False Claims Act, and other federal fraud and abuse statutes). The ANPRM indicates that CMS would regularly ensure that payment to model vendors is substantiated by physician- and hospital-submitted claims, drawing scrutiny to model vendor tracking system and record accuracy.

    The IPI Model also has significant implications for the 340B Program. First, because the IPI Model removes Medicare payments to hospitals for Part B drugs subject to the IPI Model, it removes the opportunity for hospitals to generate a substantial portion of 340B revenue previously generated from purchasing and furnishing such drugs. Second, because the 340B Program statutory prohibition on group purchasing arrangements applies to “obtaining” drugs (not purchasing drugs) through any arrangement where prices are negotiated for more entities than just the 340B participating hospital, HHS could interpret the IPI Model as creating a group purchasing arrangement for Part B drugs. If this were to occur, hospitals required to participate in the IPI Model and subject to the 340B Program prohibition on obtaining covered outpatient drugs through a group purchasing arrangement could be forced to terminate participation in the 340B Program. As noted above, CMS only acknowledges the potential for an impact on 340B ceiling price calculations and does not address the lost opportunity for 340B purchasing or the potential conflict with the group purchasing arrangement prohibition.

    Appendix A

    The ANPRM has requested comments on the following:

    Model Concept Design

    CMS seeks feedback on:

    • What limitations would be in place on the entities that could participate as vendors (e.g., pharmacies, manufacturers, providers themselves)?
    • Which countries should be included in calculating an international pricing index?
    • How frequently should international data be updated?
    • What should be the schedule for phasing in the spending target?
    • Should CMS introduce health care provider bonuses to incentivize reductions in cost or utilization relative to a benchmark?

    Model Vendors

    • Agreements between the vendors and physicians/hospitals would establish the terms of their arrangements and would include appropriate guardrails to protect all parties, including beneficiaries and the Medicare program. CMS seeks feedback on whether CMS should be a party to and/or regulate these agreements, and whether the agreements should specify obligations to ensure the physical safety and integrity of the included drugs until they are administered to an included beneficiary; how drug disposition would be handled; and data sharing methods, confidentiality requirements and potentially other requirements.
    • CMS is interested in ways to minimize any potential concerns that could arise from allowing a broader set of entities to be vendors, and how health care providers operating as vendors might be able to operate in all geographic areas included in the model. CMS seeks input on the types of entities that would be allowed to be model vendors, the potential for perverse incentives that could be introduced by potentially allowing health care providers to be model vendors and/or allowing model vendors to charge health care providers for distribution-related activities, and whether there should be guardrails in place to prevent perverse incentives.
    • CMS seeks feedback on options for model vendor payment, including whether payment should include an administration fee from CMS and whether vendors’ agreements with physicians and hospitals could include provisions for delivery fees and other vendor costs.
    • CMS invites public comment on the factors that would be necessary to allow CMS to identify entities that would most likely perform the responsibilities of a model vendor efficiently and effectively with minimal start-up time.
    • CMS seeks information about the types of entities that could serve as national vendors for the model. Should CMS require model vendors to enroll any included health care provider? If included physicians and hospitals could be model vendors, should they be required to be vendors for other health care providers, and should they have to operate on a national basis? Should any vendor be required to provide services on a national basis?
    • CMS also seeks public comment on potential guardrails that would be appropriate if manufacturers and/or health care providers could serve as model vendors. Also, should CMS receive shared savings based on the difference between a model vendor’s negotiated price and CMS’s payment amount? If so, how would CMS operationalize this shared savings approach?
    • What should be the potential responsibilities of model vendors and model participants (including physicians, hospitals, and potentially other providers and suppliers) under the model? Specifically, are there ways that vendors and model participants could collaborate to enhance quality and reduce costs?
    • What would be the ability of the potential types of entities that could be model vendors to negotiate for drug prices that would be at or below the IPI Model payment? Would certain types of entities have advantages or face additional challenges?
    • Are there processes that model vendors could use to increase their price negotiation leverage with manufacturers and lower their potential loss exposure without increasing burdens on beneficiaries, physicians and hospitals?
    • Are there unsurmountable challenges related to physicians and hospitals paying for distribution costs, and to continuing to collect beneficiary cost-sharing, including billing supplemental insurers?
    • Should physicians and hospitals receive bad debt payments if beneficiaries fail to satisfy cost-sharing obligations?
    • Is there a need for the model to include billing and dispute resolution support, and if so, what should such support include?
    • Should CMS pay the model vendors, or should providers pay the model vendors for the responsibilities associated with taking title to drugs and distributing drugs? What incentives are established if CMS pays the model vendors?
    • What should be the reasons for excluding entities from serving as a model vendor or terminating a model vendor agreement, as well as appropriate conflict of interest requirements?
    • Should the role for the model vendors include entering into value-based payment arrangements (for example, indication-based pricing or outcomes-based agreements)? And if so, should there be requirements around these arrangements?

    Model Participants, Compensation and Selected Geographic Areas

    CMS welcomes input from stakeholders on the potential approach for defining model participants, selecting geographic areas and calculating an alternative to the ASP add-on for the IPI Model. Specifically, CMS would like to receive information on which alternative add-on option is preferable and how the specific payment methodology might be designed. For example:

    • The exclusion of certain types of physician practices and/or hospital outpatient department (HOPDs) from the model. For example, should CMS consider excluding small physician practices/HOPDs (e.g., those with three or fewer physicians) from the model, or establish a low-volume threshold that would exclude those physician practices and HOPDs that fall below the threshold from participating in the model? How could CMS analyze an appropriate threshold?
    • The inclusion of additional Part B providers and suppliers that furnish and bill for any of the model’s included drugs, as well as the inclusion of providers that are paid on a cost basis, such as PPS-exempt cancer hospitals, children’s hospitals or critical access hospitals.
    • The potential approach to selecting geographic areas for the intervention and comparison groups in the model. Are there particular regions of the country that would need adjustments or exclusions from the model (for example, rural areas)?
    • How should CMS operationalize the model for large provider networks that cover some regions that are included and some that are excluded?
    • Should class of drugs, physician specialty or physician practice determine the payment amount? Are there other characteristics that should determine the alternative add-on payment amount?
    • How should a per-month alternative add-on payment be determined? How and how often should a beneficiary panel size be determined?
    • Should a bonus pool be included in the model? If so, how should the model participant bonus pool be constructed to meet the goals of the model to incentivize the use of lower-cost drugs and clinically appropriate utilization? How could a bonus pool be constructed to best protect and enhance quality under the model? How should CMS handle variable low-volume estimates and missing data values when assessing performance for purposes of a bonus pool?
    • The potential phase-in of an alternate provider compensation. Should CMS phase-in a change from percentage-based add-on payments to set payment amounts, or should set payment amounts be implemented in year one of the potential IPI Model?
    • How should CMS implement an administrative process to account for beneficiary cost-sharing for drugs that is collected by model participants?

    Included Drugs

    CMS seeks information on the following:

    • Whether the data that CMS uses to determine the inclusion of drugs and biologicals should be limited to claims from the physician’s office and hospital outpatient department settings, or whether other settings should be included.
    • The drugs to include in the model. Specifically, CMS seeks information on how to incorporate multiple source drugs.
    • Whether to include Part B drugs in all settings in which they are separately payable, or only in certain settings.
    • Whether quarterly updates for HCPCS codes included in the model are feasible. Feedback from the perspective of potential model participants and vendors is especially encouraged.
    • The best way to include new drugs in the model as they become available.
    • Whether to determine inclusion of drugs based on on-label (FDA approved) indications only, or whether CMS should consider on-label and off-label use (if supported by clinical guidelines and/or compendia).
    • CMS seeks comment as to whether aspects of mandatory participation would require physicians and hospitals to have an agreement with a single vendor or would require physicians and hospitals to obtain all drugs included in the model via a single vendor.

    Model Payment Methodology for Vendor-Supplied Drugs

    • CMS is interested in better understanding the extent to which existing data sources for international sales completely capture drug information in every international market that CMS is considering for inclusion in its payment methodology and how private market drug sales are included in countries that provide drugs through public insurance.
    • CMS seeks comment on the potential use of existing data sources and new data sources to establish the IPI and the target price.
    • CMS seeks comment on whether to examine the international pricing data and recalculate the IPI and target prices on a quarterly, annual or other basis. CMS also seeks feedback on the mechanism for reporting of international sales, and on any additional requirements that would be necessary to ensure a feasible process to collect valid international sales information for the countries that would be included in the IPI. CMS also seeks comment on ways to ensure confidentiality of reporting of international drug pricing to CMS.
    • CMS seeks comment on the countries included in its analysis to establish the IPI, target price and model payment amounts.
    • CMS seeks comment on options for calculating the model payment for new drugs that may not yet have international sales.

    CMS welcomes input from stakeholders on the potential approach for establishing model payments for included drugs based on international pricing. For example:

    • What sources of international pricing data capture drug information for the international markets that should be included in the payment methodology?
    • Are there particular data sources to establish payment amounts based on international pricing that would best support this effort?
    • How should private market drug sales included in countries that provide drugs through public insurance be included? How should CMS protect manufacturer-reported international pricing information?
    • What is the appropriate frequency for updating the international pricing information that CMS uses in calculating the Part B payment under the model?
    • How should manufacturers report international pricing information? Are there specific issues with data reporting processes that stakeholders would like CMS to consider, especially mechanisms that could reduce burden?
    • How should CMS define “manufacturer” to ensure that all relevant entities that sell single source drug products, biologics, biosimilars and, if applicable, multiple source drugs report under the model?
    • Are there areas of concern in data collection and reporting that could lead to inaccurate price calculations?
    • Which countries should be included in CMS’s international price index calculations? Should the countries vary? What characteristics should CMS consider to analyze these countries?
    • Are there specific considerations in the comparison of international and ASP prices that CMS should address?
    • How should CMS standardize data collection and reporting? What should be the target reduction to ASP payment (i.e., target price), and what should be the schedule for phasing down to the target savings amount?
    • How would such a change in payment policy affect incentives in the market? How could using international reference pricing affect innovation incentives in the biopharmaceutical market?

    Potential Foreign Market Considerations

    CMS welcomes input from stakeholders on the potential considerations related to foreign markets and the potential model payment approach that would rely on international sales data. For example:

    • What foreign market considerations should CMS consider in developing the potential IPI Model?
    • How should CMS monitor for changes in foreign markets that could affect the IPI Model?
    • What are ways to address changes in foreign sales that could affect model payment calculations?

    Beneficiary Impact and Model Monitoring

    • CMS invites public feedback on the appropriate beneficiary outcomes to monitor and how to monitor and measure such outcomes, as well as patient experience, in a way that minimizes burden on included health care providers and beneficiaries.

    Interaction with Other Federal Programs

    • CMS seeks comment on how to avoid unintended consequences from the interaction of the IPI Model with other federal programs.
    • CMS seeks public comment on how manufacturers would respond to these factors as they relate to model vendors and Medicaid drug rebates.
    • Authority for implementing innovative payment and quality models under 1115A of the Act does not completely include Title XIX waiver authority, and thus, such waiver authority does not extend to the Medicaid Drug Rebate Program, which is authorized under Title XIX at section 1927 of the Act. CMS welcomes public feedback, including from State Medicaid programs, on this issue.

    Quality Measures

    • CMS seeks information on the categories and types of quality measures CMS can incorporate in the model that are targeted and judicious, while still capturing key indicators of patient experience, access and medication management. CMS welcomes recommendations for specific measures.

    Model Evaluation

    • CMS seeks input on the evaluation approach to examine the IPI Model’s impact on Medicare spending and quality of care, including potential alternatives.

    Potential Impacts of Implementing the IPI Model

    • The model may affect AMP, ASP, best price and 340B pricing for these affected drugs, reducing both reimbursements as well as rebates. CMS seeks comment on whether it should exempt prices offered under the model from AMP and best price calculations.

     

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    More insights

  • GDPR 6 Months After Implementation: Where Are We Now?

    ARTICLE

    GDPR 6 Months After Implementation: Where Are We Now?

    October 26, 2018

    Read time: 2 min

    Key takeaways
    Overview

    Mark Schreiber and Amy Pimentel authored this bylined article on the compliance and enforcement actions around the EU General Data Protection Regulation. “A thoughtful approach to GDPR compliance can also help mitigate risk and exposure not only under the GDPR, but other global data privacy and protection regimes as well,” they wrote.

    In depth
    Authors

    Amy C. Pimentel

    Partner

    Boston

    Mark E. Schreiber

    Counsel

    Boston

    More insights

  • INSIGHT: Bring that CFC on Home: Domesticating Individually-Owned CFCs After Tax Reform

    INSIGHT: Bring that CFC on Home: Domesticating Individually-Owned CFCs After Tax Reform

    ARTICLE

    INSIGHT: Bring that CFC on Home: Domesticating Individually-Owned CFCs After Tax Reform

    October 26,2018

    Read time: 2 min

    Key takeaways
    Overview

    Leigh-Alexandra Basha and Kevin Hall authored this bylined article on the new rules governing US individuals who are shareholders of foreign corporations and options for domestication.

    In depth
    Authors

    Leigh-Alexandra Basha

    Partner

    Washington, DC

    Kevin Hall

    Partner

    Miami

    More insights

  • Prepare for the Worst, So It Won’t Happen

    ARTICLE

    Prepare for the Worst, So It Won’t Happen

    October 2018

    Read time: 2 min

    Key takeaways
    Overview

    Elysa Jacobs and Ziva Robertson authored this bylined article on the importance of Lasting Powers of Attorney and how they can prevent unforeseen problems.

    In depth
    Authors
    More insights

  • SEC Clarifies Best Practices for Board Analysis of Shareholder Proposals

    SEC Clarifies Best Practices for Board Analysis of Shareholder Proposals

    ARTICLE / CLIENT ALERT

    SEC Clarifies Best Practices for Board Analysis of Shareholder Proposals

    October 25, 2018

    Read time: 8 min

    Key takeaways
    Overview

    The SEC issued Staff Legal Bulletin No. 14J on October 23, addressing the staff’s review of no-action requests from public companies seeking to exclude shareholder proposals from their proxy materials.

    SLB 14J provides commentary on the scope and substance of analysis conducted by a company’s board of directors where the company seeks to exclude the proposal under either the “ordinary business” or “economic relevance” exclusion principles. SLB 14J also clarifies the scope of what is considered to be “micromanagement” under the “ordinary business” exclusion principle and addresses the circumstances under which proposals touching upon executive compensation may be excluded.

    In depth

    On October 23, 2018, the staff of the Division of Corporation Finance of the Securities and Exchange Commission (SEC) issued interpretive guidance, in the form of Staff Legal Bulletin No. 14J (SLB 14J), addressing the staff’s review of no-action requests from public companies that seek to exclude shareholder proposals from their proxy materials pursuant to Exchange Act Rule 14a-8.

    The most noteworthy guidance conducted by SLB 14J is its commentary on the scope and substance of analysis provided by a company’s board of directors where the company seeks to exclude the proposal under either the “ordinary business” (Rule 14a-8(i)(7)) or “economic relevance” (Rule 14a-8(i)(5)) exclusion principles. SLB 14J also clarifies the scope of what is considered to be “micromanagement” under the “ordinary business” exclusion principle and addresses the circumstances under which proposals touching upon executive compensation may be excluded.

    Background

    The “ordinary business” and “economic relevance” exclusion principles are two of the thirteen substantive bases for exclusion of a shareholder proposal provided in Rule 14a-8. When determining whether to permit the exclusion of a shareholder proposal under either of these principles, the SEC staff will determine whether the proposal is (or is not) significantly related to the company’s business or if it raises a significant policy issue that transcends the company’s ordinary business matters.

    Last year, the SEC staff issued Staff Legal Bulletin No. 14I (SLB 14I), which first suggested that a company may include a summary of the discussions and analysis of its board of directors regarding the significance of a shareholder proposal. Through SLB 14I, the SEC staff acknowledged that a determination of whether a proposal is sufficiently significant to a company’s business such that it may not be excluded under these two exclusion principles often raises difficult judgment calls. In SLB 14I, the SEC staff signaled that, although not required and not dispositive of the issue, the staff’s review of a request could benefit from the analysis and findings of a board of directors in this regard.

    Best Practices for Board Analysis

    SLB 14J expands upon Staff Legal Bulletin No. 14I (SLB 14I) by reflecting on best practices from no-action letters submitted since the release of SLB 14I. The SEC staff stated that no-action requests benefit from the inclusion of board analysis when the request includes specific substantive factors the board considered in arriving at its conclusion.

    The SEC staff also provided the following non-exclusive and non-exhaustive list of factors that have been helpful in their determination of whether a shareholder proposal should be excluded:

    • The extent to which the proposal relates to the company’s core business activities;
    • Quantitative data, including financial statement impact, related to the matter that illustrates whether or not a matter is significant to the company;
    • Whether the company has already addressed the issue in some manner, including the differences—or the delta—between the proposal’s specific request and the actions the company has already taken, and an analysis of whether the delta presents a significant policy issue for the company;
    • The extent of shareholder engagement on the issue and the level of shareholder interest expressed through that engagement;
    • Whether anyone other than the proponent has requested the type of action or information sought by the proposal; and
    • Whether the company’s shareholders have previously voted on the matter and the board’s views as to the related voting results.

    In addition, although SLB 14I noted that a no-action request may include a detailed discussion of the specific processes employed by the board to ensure that its conclusions are well-informed and well-reasoned, SLB 14J clarifies that it would be less helpful if a request detailing the board’s process does not also include a discussion of the specific factors considered.

    SLB 14J confirms that companies may still receive no-action relief under these exclusion principles without including in their request a determination of their board of directors. In public statements made after the release of SLB 14I, SEC staff indicated that companies may still look to precedent for examples of proposals and policy issues that clearly are excludable under the “ordinary business” and “economic relevance” standards.

    SLB 14J reiterates these points, stating that the inclusion of board analysis is most useful in cases in which, depending on the facts of the company, a proposal may be excludable for one company but not excludable for another, or “where the significance of a particular issue to a particular company and its shareholders may depend on factors that are not self-evident.” The SEC staff signaled that, in these instances, it may be difficult for the staff to concur that a proposal may be properly excluded without having the benefit of the board’s perspective on the matter.

    What is “Micromanagement”?

    Through SLB 14J, the SEC staff also provided guidance regarding a second prong of the “ordinary business” exclusion principle. In addition to considering the significance of a proposal’s subject matter, the “ordinary business” exclusion principle looks at the degree to which a proposal seeks to transgress the limitations of shareholder judgment by probing into detailed business matters that are generally implemented and supervised by management. Thus, shareholder proposals may be successfully challenged for their attempt to “micromanage” company affairs.

    SLB 14J cites to instances where the SEC staff has permitted the exclusion of shareholder proposals on this basis. Specifically, such proposals may be excluded where they include intricate detail, or seek to impose specific time frames or methods for implementing complex policies.

    In recent proxy seasons, the SEC staff has found that a number of shareholder proposals do not constitute micromanagement where the proposal is phrased as a request to the company board to conduct a study or publish a report analyzing the company’s role in a larger social or environmental issue. SLB 14J clarifies that such proposals may be excludable where they require that the board include certain details or if the substance of the report imposes specific timeframes or methods for implementing complex policies.

    Proposals Regarding Compensation of Senior Executives and/or Directors

    SLB 14J also provides guidance regarding the application of the “ordinary business” exclusion principle to proposals that relate to the compensation of a company’s senior executives and/or directors. As a general matter, the SEC has held that proposals involving “the management of the workforce, such as the hiring, promotion, and termination of employees,” generally relate to ordinary business matters and thus they are excludable. In contrast, a proposal that is limited in scope and tailored a company’s compensation practices for senior executives and/or directors is generally not excludable.

    SLB 14J clarifies that a proposal may be excluded, even if it touches upon senior executive and/or director compensation, if the underlying concern of the proposal relates to ordinary business matters. SLB 14J further clarifies that a proposal may be excluded if a primary aspect of the targeted compensation is broadly available or applicable to a company’s general workforce and is not sufficiently related to senior executive and/or director compensation. If such form of compensation is broadly available to the workforce, the eligibility of senior management to receive the compensation does not implicate a significant compensation matter. Finally, SLB 14J confirms that, consistent with the SEC staff’s treatment of shareholder proposals on other topics, executive compensation proposals may be excluded based on the micromanagement prong of the “ordinary business” exclusion principle, in particular where the proposal calls for intricate details, or seeks to impose specific time frames or methods for implementing complex policies.

    Authors

    Thomas P. Conaghan

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Eric Orsic

    Partner

    Chicago

    Daniel L. Woodard

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • SEC Expands Emphasis on Cybersecurity with Cyber Fraud Report

    SEC Expands Emphasis on Cybersecurity with Cyber Fraud Report

    ARTICLE / CLIENT ALERT

    SEC Expands Emphasis on Cybersecurity with Cyber Fraud Report

    October 25, 2018

    Read time: 5 min

    Key takeaways
    Overview

    The SEC has released a new report on cyber fraud, suggesting that public companies that fail to implement appropriate preventative measures risk violating the internal accounting control provisions of the Exchange Act. Companies should review their fraud prevention procedures accordingly and consider whether to conduct a comprehensive cybersecurity assessment under attorney-client privilege.

    In depth

    The Enforcement Division of the Securities and Exchange Commission (SEC) recently warned public companies that inadequate cybersecurity fraud prevention may violate the internal accounting control provisions of the Exchange Act. Following Commission guidance issued earlier this year, the most recent report reflects the agency’s continued emphasis on cybersecurity. Given this more expansive view of cybersecurity practices, public companies should ensure that internal accounting controls adequately address cybersecurity risk.

    The Report

    The SEC’s investigative report describes two types of cybersecurity scams that victimized nine public companies, which collectively lost nearly $100 million.

    In the first scam, the perpetrators used fake email accounts to request wire transfers from fake email accounts purportedly held by company executives. The emails, sent primarily to midlevel personnel, emphasized the time-sensitive nature of the request and the secretive nature of the transactions. These scams were relatively unsophisticated, and included spelling and grammatical errors. The email nevertheless fooled employees and caused losses.

    The second type of scam was more refined. In this scam, fraudsters posed as bona fide foreign vendors demanding payment. Originating from compromised vendor email addresses, the messages attached doctored invoices that contained accurate purchase order and account balance information. The attackers often were able to repeat the scams against the same victims by exploiting the vendors’ delayed action on delinquent payments.

    The SEC declined to take action against the companies in the nine instances mentioned in the report. However, the Division emphasized that the failure to prevent such frauds could run afoul of Sections 13(b)(2)(B)(i) and (iii) of the Exchanges Act. Those provisions require public companies to devise and maintain internal accounting controls sufficient to provide reasonable assurance that transactions are executed with, or that access to company assets is permitted only with, management’s authorization.

    Previous Cybersecurity Efforts

    The report reinforces the SEC’s increased emphasis on cybersecurity. The Commission recently formed a Cyber Unit within the Enforcement Division focused on these issues. In February 2018, the SEC issued guidance on cybersecurity disclosures for public companies focused on SEC reporting requirements and disclosure controls. (Read the following client alert for our detailed analysis of the February guidance.) Not long after the guidance, the SEC announced a settled action against Altaba (formerly Yahoo!) over the failure to disclose a large data breach to investors. As part of the settlement, Altaba agreed to pay a substantial $35 million penalty.

    Avoiding Enforcement

    The SEC Enforcement Division has a history of using “21A” reports like the one recently issued as warnings to public companies in advance of actual enforcement actions. As the report emphasizes, “issuers themselves are in the best position to develop internal accounting controls that account for their particular operational needs and risks.” That said, two specific compliance takeaways emerge from the report:

    • Transaction Authorization Procedures. The report highlights the importance of internal procedures for authorizing and approving wire transfers. Companies should consider multiple-authorization requirements, as well as creating or bolstering verification procedures for vendor information changes.
    • Personnel Training. Companies also should train personnel on internal procedures, emphasizing the response to red flags. Companies that already implemented phishing training may be able to adapt this training for cyber fraud, and could test the effectiveness of the training through mock emails or “phish tests.” This training should extend beyond easy-to-spot requests for wire transfers and include suspicious information requests and other suspicious behavior. The SEC noted that scammers often corresponded with unwitting company personnel to collect facts about the vendor relationship in order to change banking information and generate fake invoices. Effective data handling procedures and training could prevent such information leakage and reduce the probability of successful cyberattacks.

    Companies that update procedures and adequately train employees will have taken important steps to minimize SEC enforcement risk.

    Of course, investing in reasonable cybersecurity controls and risk management also protects public companies from misappropriation and other harm. For example, public companies can protect themselves from losses in the second type of scam—where fraudsters leverage compromised vendor email addresses to request payment—by contractually requiring vendors to indemnify them for losses resulting from compromises of vendor systems and by requiring vendors to provide prompt notification of system compromises. Public companies also should consider whether their cybersecurity risk management program is sufficiently robust to cover the range of relevant risks and vulnerabilities and whether aspects of the program, such as periodic cybersecurity assessments, need to be conducted under privilege.

    Global Trends

    The SEC’s increased focus on cybersecurity coincides with a global trend toward increased regulatory attention. As cyber-related incidents and scandals continue to dominate the headlines, domestic and international regulators rush to keep pace and demonstrate vigilance. To survive in this regulatory environment, it is essential that companies design and implement a robust cybersecurity strategy.

    McDermott has lawyers with deep experience in capital markets, SEC enforcement, and cybersecurity risk mitigation and incident response.

    Authors

    Thomas P. Conaghan

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Michael G. Morgan

    Partner

    Los Angeles, Silicon Valley

    Paul M.G. Helms

    Partner

    Chicago, Washington, DC

    Eric Orsic

    Partner

    Chicago

    More insights

  • Guidance in Proposed Regulations Expected to Jumpstart the Benefits of Qualified Opportunity Zone Investing

    Guidance in Proposed Regulations Expected to Jumpstart the Benefits of Qualified Opportunity Zone Investing

    ARTICLE / CLIENT ALERT

    Guidance in Proposed Regulations Expected to Jumpstart the Benefits of Qualified Opportunity Zone Investing

    October 25, 2018

    Read time: 11 min

    Key takeaways
    Overview

    The Tax Cuts and Jobs Act of 2017 introduced Opportunity Zone Provisions as an incentive for taxpayer investment in low-income neighborhoods and combined the benefits of both tax deferral and tax elimination. On October 19, 2018, the US Treasury released highly anticipated proposed regulations and Revenue Ruling 2018-29, which addresses certain issues associated with acquisitions of real property located in qualified opportunity zones.

    In depth

    For many years the US tax code has enabled income tax deferral in certain situations. For the ordinary taxpayer, tax deferral opportunities include contributions made to employer-sponsored 401(k) and other qualified retirement plans; for investors, tax deferral possibilities are available via IRC § 1031 exchanges of certain types of appreciated property. Income tax deferral provisions are often used by the government to encourage taxpayer behavior. Rarely does the government offer tax elimination as an additional inducement. On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the TCJA) did just that, introducing IRC § 1400Z (Opportunity Zone Provisions) which serves as an incentive for taxpayer investment in low-income neighborhoods and combines the benefits of both tax deferral and tax elimination. On October 19, 2018, the US Treasury released highly anticipated proposed regulations (the Proposed Regulations) and Revenue Ruling 2018-29, which addresses certain issues associated with acquisitions of real property located in qualified opportunity zones.

    Under the Opportunity Zone Provisions taxpayers investing capital gains in a “qualified opportunity fund” (QOF) within 180 days of realization receive three benefits; (1) tax deferral on the initial capital gain invested in the QOF, (2) potential basis step-up in the initial capital gain invested, and (3) tax elimination on the QOF investment appreciation.

    Tax on the initial capital gain is deferred until the earlier of (1) the date that the QOF investment is sold, or (2) December 31, 2026. At the conclusion of the deferral, gain will be taxed on the lesser of (1) the amount of the initial capital gain invested, over the taxpayer’s basis in the initial capital gain, or (2) the now fair market value of the initial capital gain investment, over the taxpayer’s basis. The taxpayer’s basis in the initial capital gain is zero but, if the taxpayer holds the QOF investment for at least five years at the time of the deferral conclusion, the taxpayer’s basis is increased by 10 percent of the initial capital gain. If the taxpayer had held the QOF investment for at least seven years at the time of the deferral conclusion, the basis is increased by an additional 5 percent of the initial capital gain. Any appreciation in the QOF investment is eliminated provided the investment is held for 10 years. As a note, because the deferred gain will be taxed by December 31, 2026 (at latest) and because the deferred gain must be held at least seven years in order to obtain the maximum 15 percent step-up in basis, investment in a QOF should be made on or before December 31, 2019, to achieve the maximum benefit.

    To receive these benefits, the QOF must be a corporation or partnership organized for the purpose of investing in “qualified opportunity zone property” (QOZP) and at least 90 percent of the assets of which are such property. The Proposed Regulations provide clarity on two important rules as to when cash can be treated as QOZP. Specifically, the Proposed Regulations provide that cash held as working capital will be counted as QOZP and that cash from the proceeds of selling QOZP will qualify so long as such cash is reinvested within a reasonable period of time in other QOZP. To determine whether a QOF holds 90 percent of its assets as QOZP, the assets are valued based on valuations used in audited financial statements and if the company does not utilize audited financials the value of property is equal to its initial cost basis. An investment in a qualified opportunity zone stock and qualified opportunity zone partnership interest is treated in its entirety as an investment in QOZP. A QOF failing to meet the 90 percent asset percentage test will be required to pay a penalty for each month it fails the test.

    A QOZP is defined as property that is “qualified opportunity zone stock,” a “qualified opportunity zone partnership interest,” or “qualified opportunity zone business property.”

    “Qualified opportunity zone stock” and “qualified opportunity zone partnership interest” is stock or an interest in a US corporation or partnership, respectively. The stock or interest must be acquired by the QOF after December 31, 2017, at original issue and solely in exchange for cash. At the time the stock or interest is issued, the entity must be a “qualified opportunity zone business” (QOZB) (or, in the case of a new entity, organized for purposes of being a QOZB). The entity must remain a QOZB for substantially all of the time the QOF holds the stock or interest.

    A “qualified opportunity zone business” (QOZB) is a trade or business in which substantially all of the tangible property owned or leased by the taxpayer is “qualified opportunity zone business property” (QOZBP). The Proposed Regulations provide a safe harbor clarifying that if 70 percent or more of the tangible property is QOZBP, the entity will own an adequate amount of tangible property to meet this requirement. At least 50 percent of the total QOZB’s gross income must be derived from the active conduct of such business, a “substantial portion” of the intangible property of the QOF must be used in the QOZB, and the average of the aggregate unadjusted bases of the QOZBP attributable to “nonqualified financial property” must be less than 5 percent.

    A QOZBP owned by a QOZB may not be used to provide, including the provisioning of land, for any private or commercial golf course, country club, massage parlor, hot tub facility, suntan facility, racetrack or other facility used for gambling, or any store the principal business of which is the sale of alcoholic beverages for consumption off the premises.

    A QOZBP means tangible property used in a trade or business of the QOF if (1) the property was purchased by the QOF after December 31, 2017, (2) the original use of the property in a “qualified opportunity zone” starts with the QOF, or the QOF substantially improves the property, and (3) substantially all of the use of the property was in a “qualified opportunity zone” during substantially all of the time the QOF holds the property. Future regulations will be issued to clarify what “substantially all” of the use of the property and “substantially all” of the time holding the property means. “Qualified opportunity zone business property” will be treated as substantially improved by a QOF only if during any 30-month period beginning after the date of the property’s acquisition its basis is increased by an amount exceeding its initial cost basis. In the case of real property, the Proposed Regulations and Rev. Rul. 2018-29 make an important clarification. Even though land can never be put to first use by a taxpayer, the guidance from Treasury clarifies that the price paid for land is excluded for purposes of determining whether substantial improvement occurs. For example, if a QOF acquires a parcel of real estate, which includes land with a value of $60,000 and a building with a value of $40,000, to substantially improve this property would require that the QOF incur $40,000 of improvement to the building.

    Under IRC § 1400Z-1 a “qualified opportunity zone” (QOZ) is a low-income community that is designated as a qualified opportunity zone by the state in which it is located and certified by the US Treasury.

    In sum, a QOF can invest its funds in a QOZBP through a QOZB that is a corporation or partnership, or it can invest directly in to a QOZBP. One advantage of investing directly in to a QOZBP is the ability to engage in the business listed above (e.g., golf course, country club, massage parlor, hot tub facility, suntan facility, etc.) as opposed to investing in a QOZBP owned by QOZB and which is not permitted to engage in these businesses. Other advantages of a QOF investing directly in QOZBP include the QOF’s ability to hold up to 10 percent of the QOF’s assets in cash (versus the 5 percent—plus working capital—threshold for QOZB investments) and the absence of a minimum percentage of gross income that the QOF must derive from the QOZBP (versus the requirement that a minimum of 50 percent of a QOF’s gross income be derived from QOZB investments).

    On the other hand, the advantages of a QOF investing in QOZB include the absence of a minimum percentage of QOF assets that must be invested in tangible property (versus the minimum 90 percent requirement for QOZBP investments). Thus, a QOZB can be comprised entirely of intellectual property. For example, a tech startup company located in a qualified opportunity zone could issue qualified opportunity zone stock even if the majority of its assets is comprised of intellectual property. Moreover, to the extent the QOZB owns tangible property only 70 percent of such property need be QOZBP. This flexibility on asset composition puts the QOZB investment at an advantage in many cases. The non-taxation of gain provisions under the Opportunity Zone Provisions differ from general IRC non-taxation of gain provisions (e.g., IRC § 1031) in that, generally, under the other IRC provisions deferral of gain is only permitted if the taxpayer reinvests the entirety of the sales proceeds in the new property—which includes both the portion representing basis and the portion representing gain. Taxpayers may choose to defer all or a portion of a capital gain. In contrast, the Opportunity Zone Provisions require only that the taxpayer invest the gain from a sale to receive the deferral treatment. Second, as noted above, IRC § 1400Z does not only defer the initial capital gain from tax and potentially reduce the amount of such tax, but also enables the QOF investment appreciation to never be taxed—assuming that the investment is held for 10 years. The Proposed Regulations allow an investor to pledge his or her interest in a QOF as collateral on a loan. Thus, the investor can receive a significant amount of cash from the capital gain event, while still otherwise receiving the benefits of the Opportunity Zone Provisions. Moreover, an investor can continue to defer the capital gain even if he or she were to sell the interest in the QOF within the seven year period, so long as the initial investment is entirely disposed of by the investor and is reinvested within 180 days in a replacement QOF.

    How It Works – by the Numbers

    As an example, assume an investor invests $1,000,000 of capital gain in a QOF in 2018 (QOF Investment). The deferred gain will be taxed at the earlier of (1) the date on which the taxpayer sells the QOF Investment, or (2) December 31, 2026. The amount taxed will be $1,000,000, reduced by the investor’s basis in the QOF Investment. If on the date that the QOF Investment is sold the QOF Investment is worth less than $1,000,000, then the QOF Investment is taxed at its fair market value on the date on which it is sold, reduced by the investor’s basis in the QOF Investment.

    The investor’s basis in the QOF Investment is initially zero, but if the investor holds the QOF Investment for at least five years (e.g., until 2023), the investor’s basis in the QOF Investment becomes $100,000 (10 percent of $1,000,000); if the investor holds the QOF Investment for at least seven years (e.g., until 2025), the investor’s basis in the QOF Investment becomes $150,000 (15 percent of $1,000,000). After the $1,000,000 is taxed, the taxpayer’s new basis in the QOF Investment becomes $1,000,000. Therefore, if the investor holds the QOF Investment for nine years (e.g., until 2027), the amount taxed will be any appreciation in the investment over the $1,000,000 of new basis. If the investor holds the QOF Investment for at least 10 years (e.g., until 2028), the investor’s basis in the QOF Investment is increased to the fair market value of the QSF Investment on the date on which it is sold, resulting in none of the investment appreciation being taxed (i.e. any increase in the investment over $1,000,000 is never taxed).

    The benefits to the investor in this example are (1) tax deferral of the $1,000,000 of initial capital gain invested in the QOF until the earlier of the date that the QSF investment is sold, or December 31, 2026; (2) decrease of the $1,000,000 of initial capital gain ultimately taxed to $900,000 (90 percent) or $850,000 (85 percent), depending on whether the investment is held for five or seven years, and most noteworthy (3) tax avoidance on any appreciation that the $1,000,000 of initial capital gain invested in the QOF generates, if the QOF Investment is held for 10 years.

    Conclusion

    The Opportunity Zone Provisions provide rare tax benefits for many investors. While the recently released Proposed Regulations answer many questions, additional regulations and guidance from the IRS and the US Treasury is expected before year-end.

    Authors

    John T. Lutz

    Partner

    New York – One Vanderbilt Avenue

    Michael J. Bruno

    Partner

    Miami

    More insights